Rogers Corp. (ROG)

118.35
NYSE : Electronic Technology
Prev Close 116.26
Day Low/High 116.05 / 118.63
52 Wk Low/High 105.00 / 184.00
Avg Volume 165.80K
Exchange NYSE
Shares Outstanding 18.37M
Market Cap 2.14B
EPS 4.40
P/E Ratio 27.23
Div & Yield N.A. (N.A)

Latest News

Follow-up Phase III Data Showed Genentech's Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death

Follow-up Phase III Data Showed Genentech's Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced follow-up data from the Phase III ALEX study, showing that as an initial treatment Alecensa ® (alectinib) significantly reduced the risk of disease progression or death...

Phase III IMpower150 Study Showed Genentech's TECENTRIQ And Avastin Plus Carboplatin And Paclitaxel Helped People With A Specific Type Of Metastatic Lung Cancer Live Significantly Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Phase III IMpower150 Study Showed Genentech's TECENTRIQ And Avastin Plus Carboplatin And Paclitaxel Helped People With A Specific Type Of Metastatic Lung Cancer Live Significantly Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpower150 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the...

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), A Rare Form Of Juvenile Arthritis

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), A Rare Form Of Juvenile Arthritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Approves Additional Claim For Roche Cobas Zika Test

- New claim allows for streamlined screening of pooled blood or plasma donations

Genentech To Present New Phase III Data For HEMLIBRA (emicizumab-kxwh) In People With Hemophilia A At The World Federation Of Hemophilia 2018 World Congress

Genentech To Present New Phase III Data For HEMLIBRA (emicizumab-kxwh) In People With Hemophilia A At The World Federation Of Hemophilia 2018 World Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that Phase III results for HEMLIBRA ® (emicizumab-kxwh) will be presented for the first time during the World Federation of Hemophilia (WFH) 2018 World Congress from May...

Genentech Provides Update On Phase III Study Of TECENTRIQ (Atezolizumab) And COTELLIC (Cobimetinib) In People With Heavily Pre-Treated Locally Advanced Or Metastatic Colorectal Cancer

Genentech Provides Update On Phase III Study Of TECENTRIQ (Atezolizumab) And COTELLIC (Cobimetinib) In People With Heavily Pre-Treated Locally Advanced Or Metastatic Colorectal Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMblaze370 study evaluating the combination of TECENTRIQ ® (atezolizumab) and COTELLIC ® (cobimetinib) did not meet its primary endpoint of overall...

Genentech To Present New Data From Its Industry-Leading Oncology Portfolio At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech To Present New Data From Its Industry-Leading Oncology Portfolio At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from early and late-stage clinical studies on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of...

Rogers To Participate In Oppenheimer Industrial Growth Conference

Rogers To Participate In Oppenheimer Industrial Growth Conference

Rogers Corporation (NYSE:ROG) today announced President and CEO, Bruce Hoechner, will be presenting at the Oppenheimer 13 th Annual Industrial Growth Conference in New York City on Wednesday, May 9 at 8:55 am EDT.

FDA Grants Priority Review To Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) For Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

FDA Grants Priority Review To Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) For Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Rogers Corporation Reports First Quarter 2018 Results

Rogers Corporation Reports First Quarter 2018 Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2018 first quarter.

New OCREVUS (Ocrelizumab) Data At AAN Demonstrate Significant Reductions In Disease Activity And Disability Progression In Relapsing Multiple Sclerosis

New OCREVUS (Ocrelizumab) Data At AAN Demonstrate Significant Reductions In Disease Activity And Disability Progression In Relapsing Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data were presented at the 70 th American Academy of Neurology (AAN) Annual Meeting from April 21-27 in Los Angeles, California.

Rogers Schedules Q1 2018 Earnings Call For Apr 26

Rogers Schedules Q1 2018 Earnings Call For Apr 26

Rogers Corporation (NYSE:ROG) plans to announce first quarter 2018 results on April 26 after market close, which will be followed by a conference call at 5pm ET.

Roche Launches VENTANA DP 200 Slide Scanner For Digital Pathology

Roche Launches VENTANA DP 200 Slide Scanner For Digital Pathology

- Image quality and ease of use set new standard for digital pathology, with the goal of empowering faster, better care for patients

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Carboplatin And Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Carboplatin And Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial...

Rogers Corporation Announces Chief Financial Officer Transition

Rogers Corporation Announces Chief Financial Officer Transition

Rogers Corporation (NYSE:ROG) today announced that Janice E.

FDA Approves Genentech's Lucentis (ranibizumab Injection) 0.3 Mg Prefilled Syringe For Diabetic Macular Edema And Diabetic Retinopathy

FDA Approves Genentech's Lucentis (ranibizumab Injection) 0.3 Mg Prefilled Syringe For Diabetic Macular Edema And Diabetic Retinopathy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Squamous Lung Cancer

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Squamous Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination...

Roche Launches The New Cobas M 511 Analyzer, Signaling A New Era In Hematology Testing

Roche Launches The New Cobas M 511 Analyzer, Signaling A New Era In Hematology Testing

Clinicians to benefit from integrated workflow and faster access to abnormal results

Roche Achieves Two Major Milestones In The Evolution Of Decision Support Platform

Roche Achieves Two Major Milestones In The Evolution Of Decision Support Platform

-- HITRUST CSF® certification granted for NAVIFY™ Tumor Board solution

Rogers Corporation Reports Fourth Quarter 2017 And Full Year Results

Rogers Corporation Reports Fourth Quarter 2017 And Full Year Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2017 full year and fourth quarter.

Rogers Schedules Q4 & Full Year 2017 Earnings Call For Feb 27

Rogers Schedules Q4 & Full Year 2017 Earnings Call For Feb 27

Rogers Corporation (NYSE:ROG) plans to announce fourth quarter and full year 2017 results on February 27 after market close, which will be followed by a conference call at 5pm ET.

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Roche Receives FDA Clearance For Factor II And Factor V Test On The Cobas® 4800 System

Roche Receives FDA Clearance For Factor II And Factor V Test On The Cobas® 4800 System

- Provides a rapid workflow to aid in the diagnosis of patients with suspected thrombophilia

Roche Diagnostics Recognizes Wisconsin Diagnostic Laboratories As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Wisconsin Diagnostic Laboratories As Roche Molecular Center Of Excellence

Institution joins strategic network designed to help accelerate advancement of new methods in molecular diagnostics, anatomic pathology and sequencing

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II BOULEVARD study.

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) as a first-line...

Roche Launches CE-marked VENTANA MMR IHC Panel For Patients Diagnosed With Colorectal Cancer

Roche Launches CE-marked VENTANA MMR IHC Panel For Patients Diagnosed With Colorectal Cancer

-- The VENTANA MMR IHC Panel1 helps differentiate between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer

TheStreet Quant Rating: B (Buy)